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associated with bacteriological eradication in AECOPD at 
EOT and in the following 8 weeks.
Methods Sputum bacteriological outcomes (i.e., eradi-
cation, persistence, superinfection, reinfection) from 
AECOPD patients (N = 1352) who were randomized to 
receive moxifloxacin or amoxicillin/clavulanate in the 
MAESTRAL study were compared. Independent predic-
tors of bacterial presence in sputum at exacerbation and 
determinants for bacteriological eradication were analyzed 
by logistic regression and receiver operating characteristic 
(ROC) analyses.
Results Significantly greater bacteriological eradication 
with moxifloxacin was mainly driven by superior Haemo-
philus influenzae eradication (P = 0.002, EOT). Baseline 
clinical factors were a weak predictor of the presence of 
pathogens in sputum (AUCROC = 0.593). On multivariate 
analysis, poorer bacterial eradication was associated with 
antibiotic resistance (P = 0.0001), systemic steroid use 
(P = 0.0024) and presence of P. aeruginosa (P = 0.0282).
Conclusions Since clinical prediction of bacterial pres-
ence in sputum at AECOPD is poor, sputum microbiologi-
cal analysis should be considered for guiding antibiotic 
therapy in moderate-to-severe AECOPD, particularly in 
those who received concomitant systemic corticosteroids or 
are at risk for infection with antibiotic-resistant bacteria.
Keywords Bacteriological outcomes · Beta-lactams · 
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Introduction
Exacerbations of chronic obstructive pulmonary disease 
(COPD) lead to a progressive decline in lung function, with 
Abstract 
Purpose Changes in sputum microbiology follow-
ing antibiotic treatment of acute exacerbations of chronic 
obstructive pulmonary disease (AECOPD), including pat-
terns of bacteriological relapse and superinfection are not 
well understood. Sputum microbiology at exacerbation is 
not routinely performed, but pathogen presence and spe-
cies are determinants of outcomes. Therefore, we deter-
mined whether baseline clinical factors could predict the 
presence of bacterial pathogens at exacerbation. Bacterial 
eradication at end of treatment (EOT) is associated with 
clinical resolution of exacerbation. We determined the 
clinical, microbiological and therapeutic factors that were 
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even a single episode of exacerbation having a prolonged 
effect on health status [1]. Ultimately, 5-year survival is 
significantly reduced in patients who experience frequent 
exacerbations of COPD, particularly if they require hos-
pitalization [2]. Exacerbations can be of bacterial, viral or 
non-infectious etiology, and a significant proportion can be 
multi-factorial [3, 4].
The controversy regarding the use of antibiotics in the 
treatment of acute exacerbations of COPD (AECOPD) has 
now been largely resolved, with increasing evidence of 
bacterial causation and of clinical benefits with antibiotic 
treatment [5, 6]. Moxifloxacin (MXF) and amoxicillin/cla-
vulanic acid (AMC) are currently recommended antibiotics 
for the treatment of AECOPD in patients at risk for poor 
outcome [5, 7, 8]. These two antibiotics demonstrated simi-
lar clinical efficacy in the recently completed MAESTRAL 
trial in COPD outpatients with Anthonisen type I exacerba-
tions [9].
Several novel observations were made in the MAES-
TRAL study. Approximately 50 % of patients had a patho-
gen isolated at baseline, and in this subgroup moxifloxacin 
was superior to amoxicillin/clavulanate in reducing clinical 
failures and relapses over the 8-week post-treatment period 
[9]. This may be the result of significantly higher bacterio-
logical eradication rate at the end of antibiotic treatment 
with moxifloxacin compared with amoxicillin/clavulanic 
acid [9].
Although the efficacy of systemic corticosteroids is well 
established in hospitalized AECOPD patients, their role in 
outpatients remains unclear. Corticosteroids may influence 
clearance of bacteria by the immune system and result in 
incomplete eradication of pathogens leading to relapses. In 
MAESTRAL, higher clinical failure rate was observed in 
patients with co-administration of systemic corticosteroids 
compared with those who did not receive systemic steroids 
[9].
Additional analyses of the MAESTRAL database pre-
sented here were done to explore these interesting obser-
vations further. We analyzed in detail changes in microbi-
ology after an AECOPD during the 8-week study period, 
including patterns of bacteriological relapse and superin-
fection. We aimed to identify the baseline clinical factors 
(in addition to sputum purulence) which could predict the 
presence of bacteria in sputum at exacerbation and thus 
guide antibiotic treatment choices in AECOPD. We inves-
tigated which baseline and therapy factors were associ-
ated with bacteriological outcomes at EOT and 8 weeks 
post-therapy. We analyzed further the relationship between 
sputum microbiology and clinical outcome, especially for 
Pseudomonas aeruginosa.
We also investigated whether there was an interac-
tion between systemic corticosteroid use and sputum 
microbiology that may account for the higher clinical fail-
ure rate in corticosteroid-treated patients.
Patients and methods
Study design
As previously reported, MAESTRAL [NCT00656747] 
was a prospective, multinational, multicenter, randomized, 
double-blind, double-dummy, controlled study comparing 
the efficacy of 5 days of MXF 400 mg orally (PO) once-
daily with 7 days of AMC 875/125 mg PO twice daily in 
outpatients experiencing an AECOPD [9]. Prior to ran-
domization, patients were stratified according to the co-
administration of oral corticosteroids (CS) for the current 
AECOPD, prescribed at the treating physician’s discretion. 
Full details of the study design, protocol, primary and sec-
ondary outcomes and definitions of clinical response have 
been reported previously [9, 10]. The primary endpoint 
was clinical failure rate at 8 weeks post-therapy in the per-
protocol (PP) population [9]. Clinical failure was defined 
as the requirement for additional or alternate treatment 
with systemic antibiotics and/or systemic corticosteroids 
(including increased dose or duration of treatment), and/or 
hospitalization within 8 weeks post-therapy for an exacer-
bation of respiratory symptoms [9].
Patient populations
Full details of the populations assessed in the MAESTRAL 
study have been published previously [9]. Briefly, patients, 
aged ≥60 years, had moderate-to-severe COPD, forced 
expiratory volume in 1 s (FEV1) ≤60 %, ≥2 exacerbations 
in the past 12 months and an Anthonisen type I exacerba-
tion (i.e., increased dyspnea, increased volume and puru-
lence of sputum). The populations assessed in this analysis 
were the PP with pathogens [all patients valid for the PP 
population with at least one pre-therapy potentially patho-
genic bacteria (PPB) in sputum), ITT with pathogens (all 
patients valid for the ITT population with at least one pre-
therapy PPB in sputum), and the complete ITT population.
Microbiology
Spontaneous sputum samples, obtained from all patients at 
enrolment and each subsequent clinic visit (if obtainable), 
were assessed in a local laboratory by Gram stain and cul-
ture. The investigator had to confirm macroscopically the 
purulence of the sputum sample and also graded it as either 
yellow or green or rust (according to the provided color 
chart). Microscopic quality assessments of all samples 
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were carried out, and squamous epithelial and polymor-
phonuclear cell counts were assessed semi-quantitatively. 
Pure sub-cultures of PPB which were predefined in the 
study protocol (Haemophilus spp., Streptococcus pneu-
moniae, Moraxella catarrhalis, P. aeruginosa, Klebsiella 
spp., Enterobacteriaceae spp., and Staphylococcus aureus) 
isolated on culture from these sputum samples were then 
frozen and forwarded to a central microbiology labora-
tory. There, the identity of bacteria was confirmed followed 
by determination of minimum inhibitory concentrations 
(MICs) for MXF, AMC, and a series of other antibiotics by 
the reference Clinical Laboratory Standards Institute broth 
dilution method [11].
MICs for penicillin were determined for S. pneumoniae 
and S. aureus isolates were tested for oxacillin susceptibil-
ity to determine methicillin-resistant S. aureus (MRSA) 
status. Beta-lactamase production for H. influenzae was 
classified by the ampicillin MIC, with a value of ≥2 mg/L 
considered positive.
Bacteriological response rates were assessed during 
therapy, at EOT and at 4 and 8 weeks post-therapy. Bacte-
riological responses to therapy were defined as the follow-
ing: (1) bacteriological eradication without superinfection 
or reinfection—initial causative pathogen(s) absent, no new 
pathogen isolated after start of study; (2) presumed eradi-
cation—absence of appropriate culture material for evalua-
tion because the subject has clinically improved on therapy; 
(3) persistence—initial causative pathogen(s) still present; 
(4) presumed persistence—absence of appropriate culture 
material for evaluation in a subject who has not clinically 
improved on therapy; (5) bacteriological eradication with 
superinfection—initial causative pathogen(s) absent, a new 
pathogen isolated during treatment or at EOT; (6) bacte-
riological eradication with reinfection—initial causative 
pathogen(s) absent, a new pathogen isolated after EOT; 
(7) eradication with recurrence—original causative organ-
ism absent at EOT, but reappearance of the same organism 
at or before 8 weeks post-therapy; (8) continued eradica-
tion—the causative organism(s) is absent at this time point; 
(9) continued presumed eradication—the absence of appro-
priate culture material for evaluation because the patient 
has clinically improved; (10) indeterminate—bacterial 
response to the study drug was not evaluable. Bacteriologi-
cal success was defined as the sum of confirmed and pre-
sumed eradication of bacteria. Bacteriological failure was 
defined as the sum of persistence, presumed persistence, 
superinfection, reinfection and indeterminate outcomes.
Statistical analyses
Bacteriological outcomes were summarized by bacterial 
species and treatment group using descriptive statistics. 
Bacteriological outcomes by subject in the MXF and AMC 
arms were compared to test non-inferiority (at 6 % level 
with Mantel–Haenszel test).
Clinical and bacteriological outcomes in patients with 
Pseudomonas aeruginosa isolated from sputum at baseline 
were compared with those without this pathogen. The inter-
action of PPB presence in sputum and systemic steroid use 
at the different time points with regard to clinical failure 
rate was analyzed by one-way ANOVA.
Pre-therapy factors (see Supplementary Table 1; i.e., 
demographic, medical history, anamnesis related to exac-
erbation, medications, sputum characteristics, organisms 
related to exacerbation, AECB-SS questionnaire details) 
were analyzed using univariate and multivariate logistic 
regression analyses to evaluate their association with the 
presence of PPB in sputum at enrolment and with bacte-
riological endpoints. A receiver operating characteristic 
(ROC) analysis was also performed to determine whether 
the combination of the independent risk factors would pro-
vide a reliable model to predict the presence of pathogens 
in the airways during an acute exacerbation. The independ-
ent predictors for presence of bacteria were also evaluated 
in terms of their frequency. For categorical variables P 
value calculation was based on the presence or absence (or 
predefined categories) of the variable. For continuous vari-
ables P value calculation was based on individual values of 
the independent variable.
Pre-therapy factors were combined with on therapy fac-
tors to determine their relationship with bacteriological 




Bacteriological demographics and etiology
Of the identified potential pathogens at baseline in N = 662 
patients, 23.4 % were Gram-positive, 35.3 % were Enter-
obacteriaceae and 59.8 % were other Gram-negative 
(Table 1). Patients could have more than one isolated 
species at baseline (monomicrobial infection: 82.6 %; 
547/662 patients; polymicrobial infection: 17.4 %; 115/662 
patients). The pattern of frequency and types of the most 
frequent isolates were similar in both treatment groups.
Bacterial persistence
The most frequent persisting pathogens over the course 
of the study period in either MXF or AMC group were P. 
aeruginosa, E. coli, K. pneumoniae, S. marcescens, M. 
catarrhalis and A. baumannii. Among these persisting 
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Table 1  Distribution of all baseline potential pathogens by rank order grouping of species and main species (ITT with pathogens population, 
N = 662)
Species Total n/N (%) Moxifloxacin n/N (%) Amoxicillin/clavulanic acid n/N (%)
Totalpatients N = 662 N = 327 N = 335
Totalbacteria N = 785 N = 385 N = 400
Gram-positive
 Total (% of patients)a 155 (23.4) 80 (24.5) 75 (22.4)
 Streptococcus pneumoniae 87 (13.1) 49 (15.0) 38 (11.3)
 Staphylococcus aureus 43 (6.5) 23 (7.0) 20 (6.0)
 Streptococcus spp. 8 (1.2) 3 (0.9) 5 (1.5)
 Streptococcus viridans group 5 (0.8) 1 (0.3) 4 (1.2)
 Streptococcus agalactiae 4 (0.6) 2 (0.6) 2 (0.6)
 Streptococcus pyogenes 3 (0.5) 0 (0) 3 (0.9)
 Streptococcus mitis 1 (0.2) 1 (0.3) 0 (0)
 Enterococcus faecalis 1 (0.2) 1 (0.3) 0 (0)
 Enterococcus faecium 1 (0.2) 0 (0) 1 (0.3)
 Staphylococcus epidermidis 1 (0.2) 0 (0) 1 (0.3)
 Staphylococcus haemolyticus 1 (0.2) 0 (0) 1 (0.3)
Gram-negative non-Enterobacteriaceae
 Total (% of patients)a 396 (59.8) 191 (58.4) 205 (61.2)
 Haemophilus influenzae 140 (21.1) 65 (19.9) 75 (22.4)
 Pseudomonas aeruginosa 111 (16.8) 57 (17.4) 54 (16.1)
 Moraxella catarrhalis 79 (11.9) 36 (11.0) 43 (12.8)
 Acinetobacter baumannii 18 (2.7) 12 (3.7) 6 (1.8)
 Haemophilus parainfluenzae 18 (2.7) 5 (1.5) 13 (3.9)
 Stenotrophomonas maltophilia 8 (1.2) 2 (0.6) 6 (1.8)
 Acinetobacter lwoffii 4 (0.6) 3 (0.9) 1 (0.3)
 Morganella morganii 3 (0.5) 3 (0.9) 0 (0.0)
 Haemophilus spp. 3 (0.5) 2 (0.6) 1 (0.3)
 Burkholderia cepacia 2 (0.3) 1 (0.3) 1 (0.3)
 Moraxella spp. 2 (0.3) 0 (0) 2 (0.6)
 Moraxella osloensis 2 (0.3) 2 (0.6) 0 (0.0)
 Pseudomonas fluorescens 1 (0.2) 0 (0.0) 1 (0.3)
 Pseudomonas putida 1 (0.2) 0 (0.0) 1 (0.3)
 Alcaligenes xylosoxidans 1 (0.2) 0 (0.0) 1 (0.3)
 Haemophilus haemolyticus 1 (0.2) 1 (0.3) 0 (0.0)
 Haemophilus parahaemolyticus 1 (0.2) 1 (0.3) 0 (0.0)
 Bordetella bronchiseptica 1 (0.2) 1 (0.3) 0 (0.0)
Enterobacteriaceae
 Total (% of patients)a 234 (35.3) 114 (34.9) 120 (35.8)
 Klebsiella pneumoniae 84 (12.7) 36 (11.0) 48 (14.3)
 Escherichia coli 37 (5.6) 21 (6.4) 16 (4.8)
 Serratia marcescens 28 (4.2) 14 (4.3) 14 (4.2)
 Enterobacter cloacae 19 (2.9) 11 (3.4) 8 (2.4)
 Enterobacter aerogenes 16 (2.4) 8 (2.4) 8 (2.4)
 Klebsiella oxytoca 15 (2.3) 11 (3.4) 4 (1.2)
 Proteus mirabilis 13 (2.0) 4 (1.2) 9 (2.7)
 Citrobacter koseri 13 (2.0) 6 (1.8) 7 (2.1)
 Proteus vulgaris 2 (0.3) 0 (0.0) 2 (0.6)
 Citrobacter freundii 2 (0.3) 1 (0.3) 1 (0.3)
 Citrobacter amalonaticus 2 (0.3) 1 (0.3) 1 (0.3)
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pathogens, the frequency of H. influenzae isolation was 
lower in MFX group compared with AMC group during the 
entire study (P < 0.05 at EOT; Supplementary Table 2).
Superinfections and reinfections
A total of 148 patients had superinfection up to EOT, 65 
(9.6 % of 677 ITT patients) in the MXF group and 83 
(12.3 % of 675 ITT patients) in the AMC group (P = 0.11) 
(see Supplementary Table 3 for detailed listing of patho-
gens). The most common superinfecting organisms (≥10 % 
of total number of superinfecting bacteria) in both groups 
were P. aeruginosa, K. pneumoniae, H. influenzae, A. bau-
mannii, M. catarrhalis, S. aureus, E. coli, E. cloacae, K. 
oxytoca, S. pneumoniae and S. marcescens. Among these 
pathogens, significant differences between the two arms 
(MXF vs AMC) were seen for H. influenzae (0.9 vs 2.7 %, 
P = 0.013), K. oxytoca (0.2 vs 2.1 %, P < 0.001) and E. 
cloacae (0.6 vs 2.1 %, P = 0.017), respectively.
A total of 119 reinfections were observed up to 8 weeks 
post-therapy, and the rate was very similar in the two 
treatment groups [n = 58 (8.6 %) in MXF group and 
n = 61 (9.0 %) in AMC group].The most common (≥10 % 
of total number of reinfecting bacteria) species were P. 
aeruginosa, K. pneumoniae, S. pneumoniae, M. catarrha-
lis, H. influenzae, K. oxytoca, E. coli, E. cloacae and S. 
marcescens (Supplementary Table 4). A significant differ-
ence between the two arms (MXF vs AMC) was seen for 
H. influenzae (1.0 vs 2.8 %, P = 0.017), while numerical 
(not significant) differences were seen for M. catarrhalis 
(2.4 vs 1.2 %), S. aureus (1.0 vs 0.3 %), K. oxytoca (0.7 
vs 1.6 %), E. coli (1.2 vs 0.6 %) and E. cloacae (0.4 vs 
1.3 %).
In vitro susceptibility of persisting, reinfecting 
and superinfecting pathogens
MIC changes during therapy or up to 8 weeks post-therapy 
were rare in persisting or reinfecting organisms and were 
minor in both treatment groups. Susceptibility patterns of 
superinfecting organisms did not differ from those of pre-
therapy pathogens (Supplementary Table 5).
Table 1  continued
Species Total n/N (%) Moxifloxacin n/N (%) Amoxicillin/clavulanic acid n/N (%)
 Klebsiella ozaenae 1 (0.2) 0 (0.0) 1 (0.3)
 Enterobacter hormaechei 1 (0.2) 1 (0.3) 0 (0.0)
 Serratia liquefaciens 1 (0.2) 0 (0.0) 1 (0.3)
P values were >0.05 for all potential pathogens; species >10 % of total are bolded
n number of patients with potential pathogens isolated at baseline, N total number of patients, ITT intent-to-treat, spp species
a Total number of patients with potential pathogen group at baseline
Fig. 1  Bacteriological successa 
of H. influenzae by timepoint 
(ITT with pathogens popula-
tion, N = 662); filled square 
moxifloxacin; unfilled circle 
amoxicillin/clavulanic acid. 





































P=0.002 vs amoxicillin/clavulanic acid
P=0.046 vs amoxicillin/clavulanic acid
P=0.196 during therapy
P=0.054 at 4 weeks post-therapy
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Bacteriological outcomes by species
For individual pathogens, the most striking and consist-
ent difference in bacteriological eradication between the 2 
treatments was seen with H. influenzae (Fig. 1). The most 
pronounced difference in H. influenzae eradication rates 
between MXF and AMC was observed at EOT (89.2 vs 
66.7 %, P = 0.002); however, over the 8-week post-therapy 
period the difference was maintained.
Changes in bacteriological success for the most prevalent 
6 pathogens over the study period in the ITT with pathogens 
and PP with pathogens populations are provided in the Sup-
plementary Material (Supplementary Table 6). There were 
no statistically significant differences observed between the 
2 treatments for any other pathogens at any time point. A 
trend towards higher eradication rates for P. aeruginosa at 
8 weeks post-therapy in the PP with pathogens population 
(P = 0.06) was seen with MXF compared with AMC. There 
was also a trend for eradication rates for M. catarrhalis 
to be higher in the AMC group than in the MXF group at 
4 weeks (P > 0.1) and 8 weeks (P = 0.08) post-therapy in 
the ITT with pathogens population; this difference in eradi-
cation rate was seen in the PP with pathogens population 
only at 8 weeks post-therapy (Supplementary Table 6).
Predictive factors for bacterial isolation at enrolment
In the univariate analyses, several factors were found to be 
predictive of bacterial isolation from sputum at enrolment 
(P < 0.1, included in Supplementary Table 1). Multivariate 
logistic regression analysis revealed seven factors that 
were independently associated with the presence of PPB at 
enrolment (Table 2).
When the pre-therapy clinical risk factors were pooled, 
presence of at least four factors provided a probability 
of the presence of PPB at baseline of 60.9 % (173/284 
patients) (Fig. 2). When five or more factors were present, 
the probability increased to 64.0 % (48/75 patients). There 
were only three patients with six factors and no patient with 
all seven factors present simultaneously. The ROC curve 
analysis suggested that the combination of these seven 
independent risk factors would poorly predict the presence 
of pathogens in the airways during an acute exacerbation 
(area under the curve (AUC) = 0.593].
Table 2  Pre-therapy risk 
factors independently 
associated with isolation of 
potentially pathogenic bacteria 
at enrolment (ITT population, 
N = 1352)
a Multivariate analysis
AECB-SS Acute Exacerbation of Chronic Bronchitis Symptom Scale, FEV1 forced expiratory volume in 
1 s, ITT intent-to-treat
Risk factors Bacteria P valuea
Present (%) Absent (%)
Age ≥65 years <65 years 0.003
51.6 42.0
History of cardiopulmonary disease Yes No 0.016
58.6 47.7
FEV1 percent predicted ≥30 % <30 % 0.0303
50.6 44.0
Sputum viscosity Very thick Not very thick 0.0147
55.6 48.1
Color of sputum (recorded as part of AECB-SS) Green or brown Other colors 0.0214
54.4 47.0
Wheeze present Yes No 0.0327
50.4 43.0









































Fig. 2  Risk of presence of bacteria in sputum based on number of 
risk factors (ITT with pathogens population, N = 662). ITT intent-to-
treat
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Predictive factors at EOT and at 8 weeks post-therapy 
for confirmed bacteriological eradication from sputum 
and bacteriological success including presumed 
eradication
Using multivariate analyses, several pre- and on-therapy 
independent factors were found to be significantly associ-
ated with confirmed eradication of bacteria (vs lack of erad-
ication) in the sputum at EOT and 8 weeks post-therapy.
At EOT, patients who received MXF, who had been 
treated previously with a course of antibiotic in the last 
3 months, had a history of respiratory failure or a dura-
tion of chronic bronchitis of ≥10 years were more likely 
to eradicate bacteria from their airways at EOT (Fig. 3a). 
However, patients who were also treated with systemic cor-
ticosteroids for the current exacerbation or were infected 
with P. aeruginosa were less likely to eradicate bacteria 
(Fig. 3a). Patients were more likely to remain pathogen 
free at 8 weeks post-therapy if they received MXF instead 
of AMC or had been treated previously with a course of 
antibiotic in the last 3 months (Fig. 3b). The analyses also 
revealed that higher volume of sputum was significantly 
associated with bacteriological success at EOT or up to 
8 weeks post-therapy (Fig. 3a, b).
Additional analyses were conducted to assess factors 
related to bacteriological success (when, in addition to 
confirmed eradication, presumed eradication [see defini-
tion above] was also taken into account). In the multivariate 
analysis for EOT outcomes, patients with a body mass index 
(BMI) at normal range or above (e.g., ≥20 kg/m2) were 
more likely to achieve bacteriological success [odds ratio 
(OR): 1.05, P = 0.0044, 95 % confidence interval (CI) 1.02, 
1.10]. However, bacteriological success was less likely with 
infection by pathogens resistant to study drugs (OR 0.45, 
P = 0.0001, 95 % CI 0.30, 0.68) or among patients treated 
with long-acting β-agonists (LABA) (OR 0.55, P = 0.0024, 
95 % CI 0.37, 0.81). At 8 weeks post-therapy, patients with a 
body temperature ≥36 °C were more likely to achieve bacte-
riological success (OR 1.89, P < 0.0001, 95 % CI 1.37, 2.63). 
However, bacteriological success was less likely if patients 
were treated with LABA (OR 0.44, P < 0.0001, 95 % CI 
0.29, 0.65) or systemic corticosteroids for the current exacer-
bation (OR 0.70, P = 0.0405, 95 % CI 0.50, 0.98).
Exacerbations with P. aeruginosa infection
Comparison of the baseline characteristics of patients with 
and without P. aeruginosa versus the overall ITT popula-
tion showed no major differences (Table 3). Clinical fail-
ure at 8 weeks post-therapy in patients with P. aeruginosa 
was 21.1 % in the MXF and 29.6 % in the AMC treatment 
groups (P = 0.298), while clinical failure rates were simi-
lar in patients without P. aeruginosa infection (20.3 % in 
MXF and 20.9 % in AMC treatment groups, respectively, 
P = 0.790) (Supplementary Fig. 1).
Clinical outcome according to pathogen presence 
in sputum and systemic corticosteroid use
We examined the effects of the interaction of systemic 
corticosteroid use (CS, + or −) and pathogen presence 
(P, + or −) in sputum on clinical outcomes at different time 
points. Four groups of patients were identified, CS+ P+, 
CS+ P−, CS− P+, CS− P−. At EOT, clinical failure rate 
in the CS+ P+ group was higher (P < 0.001) than in the 
other 3 groups. At 4 and 8 weeks post-therapy, both CS+ 
groups demonstrated worse clinical outcomes than CS− 
groups (4 weeks: P < 0.001; 8 weeks: P < 0.001, Fig. 4).
Discussion
Clinical outcomes have been the focus of many recent 
AECOPD trials. The importance of bacteria in causing 
exacerbations and contributing to chronic inflammation in 
COPD is widely recognized; therefore, the dynamics of 
bacterial infection following an AECOPD and the impact 
of our treatment choices on these dynamics need to be 
better understood. The current bacteriological results of 
the MAESTRAL study, which was a randomized, dou-
ble-blind, double-dummy, controlled trial enrolling 1352 
AECOPD outpatients, has yielded important observations. 
Analyses of the bacteriological dataset, and correlating it 
with clinical variables, showed that (1) MXF treatment ver-
sus AMC treatment had significantly higher and sustained 
eradicaton of Haemophilus influenzae, which is the most 
prevalent bacterial pathogen in AECOPD; (2) the investi-
gated pre-therapy clinical factors are poorly predictive of 
the presence of pathogens in sputum; (3) the presence of 
Pseudomonas aeruginosa in the airways is associated with 
lack of bacteriological eradication in patients who were 
treated with antibiotics according to current guidelines; (4) 
concomitant systemic corticosteroid treatment is associated 
with poorer bacteriological eradication and higher clinical 
failure rate; (5) LABA treatment was also associated with 
higher risk of bacteriological failure at the end of therapy 
and it was maintained up to 8 weeks post-therapy, and (6) 
the presence of organisms in sputum pre-therapy resistant 
to study drugs was more likely to lead to bacteriological 
failure.
The spectrum and frequency of pathogens isolated in the 
MAESTRAL study were consistent with what is expected 
in COPD patients with moderate-to-severe disease [3, 9, 
12–16], and no unusual resistance patterns were identified 
[9]. However, a higher frequency of pathogen isolation in 
patients with Anthonisen type I exacerbations might have 
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Fig. 3  a Prognostic factors 
associated with confirmed 
bacterial eradication at end of 
therapy (ITT with pathogens 
population, N = 662). aAt 
current exacerbation, bcontinu-
ous value; AMC amoxicillin/
clavulanic acid; CI confidence 
interval, EOT end of therapy, 
ITT intent-to-treat, MXF moxi-
floxacin. b Prognostic factors 
associated with confirmed 
bacteriological eradication 
at 8 weeks post-therapy (ITT 
with pathogens population, 
N = 662). ITT intent-to-treat, 
CI confidence interval, OR odds 
ratio
Treatment with MXF vs AMC
Co-administration of systemic 
corticosteroid a (yes vs no)
Previous antibiotic use 
(yes vs no)
Presence of P. aeruginosa
pre-therapy (yes vs no)
History of respiratory 
failure (yes vs no)
Sputum volume
(6–15 ml vs ≤5 ml)
Sputum volume
(16–30 ml vs ≤5 ml)
Sputum volume
(31–50 ml vs ≤5 ml)
Sputum volume
(>50 ml vs ≤5 ml)
Longer duration of chronic 
bronchitis b
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0
P=0.0332, 95% CI: 1.03, 2.09
P=0.0024, 95% CI: 0.31, 0.81
P=0.0004, 95% CI: 1.35, 2.84
P=0.0282, 95% CI: 0.34, 0.94
P=0.0055, 95% CI: 1.28, 4.11
P=0.045, 95% CI: 1.01, 1.04




95% CI: 1.05, 5.84







Treatment with MXF vs AMC
Previous antibiotic use (yes 
vs no)
Sputum volume
(6–15 ml vs ≤5 ml)
Sputum volume
(16–30 ml vs ≤5 ml)
Sputum volume
(31–50 ml vs ≤5 ml)
Sputum volume
(>50 ml vs ≤5 ml)
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0
P=0.0332, 95% CI: 1.08, 2.72
P=0.0024, 95% CI: 1.09, 2.84







95% CI: 0.66, 5.92
95% CI: 0.88, 5.91
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been expected. Of note, viral exacerbations were not inves-
tigated in the study. However, it is becoming clear that spu-
tum cultures are relatively insensitive for detecting PPBs in 
these patients and the rate of detection may be substantially 
increased by the addition of molecular detection methods 
[15, 16]. Furthermore, with new molecular technologies 
that rapidly reveal the entire microbiome in the sputum or 
the airway samples of these patients [17], more accurate 
information on the infectious etiology is expected in the 
future [18].
Overall bacteriological success rates were higher for 
MXF vs AMC throughout the study with the difference 
between treatments being significant during therapy and at 
EOT [9]. Surprisingly, as shown in the current analyses this 
difference was mainly driven by significantly higher eradi-
cation of H. influenzae with MXF, a pathogen sensitive to 
Table 3  Demographics and baseline characteristics of patients with or without P. aeruginosa isolated at enrolment (ITT population, N = 1352)
a N = 110
b N = 1347
BMI body mass index, FEV1 forced expiratory volume in 1 s, ITT intent-to-treat, SD standard deviation
Characteristics With P. aeruginosa (N = 111) Without P. aeruginosa (N = 1241) All patients (N = 1352)
Male sex, n (%) 95 (85.6) 984 (79.3) 542 (79.8)
Age (years), mean ± SD 70.9 ± 7.3 69.4 ± 6.7 69.6 ± 6.7
 Range 60–88 59–93 59–93
 ≥65 years, n (%) 85 (76.6) 893 (72.0) 978 (72.3)
BMI (kg/m2), mean ± SD 23.8 ± 4.9 25.0 ± 5.2 24.8 ± 5.3
Systemic corticosteroid use for current  
exacerbation, n (%)
45 (40.5) 430 (34.6) 475 (35.1)
Previous antimicrobial use, n (%) 36 (32.4) 426 (34.3) 462 (34.2)
Duration of chronic bronchitis (years), mean ± SD 9.6 ± 7.1 9.3 ± 7.5 9.4 ± 7.5
FEV1 (L), mean ± SD 0.96 ± 0.35 0.98 ± 0.37 0.98 ± 0.36b
FEV1,  % predicted, mean ± SD 38.3 ± 11.25 38.6 ± 11.7 38.6 ± 11.6
 FEV1 < 30 %, n (%) 29 (26.4) 310 (25.0) 339 (25.1)
 FEV1 ≥ 30 %, n (%) 81 (73.6)a 927 (74.7) 1008 (74.6)
Cardiopulmonary disease, n (%)
 Yes 14 (12.6) 143 (11.5) 157 (11.6)
 No 97 (87.4) 1098 (88.5) 1195 (88.4)
Exacerbations in previous year
 Mean ± SD 2.6 ± 1.5 2.5 ± 1.0 2.5 ± 1.1
 Range 2–15 1–10 1–15
Fig. 4  Clinical failurea rates in 
patients over time with or with-
out corticosteroid use and by 
causative pathogen presence or 
absence at enrolment in sputum 
(ITT population, N = 1352); 
unfilled triangle CS+ patho-
gen present (n = 245); filled 
diamond CS+ pathogen absent 
(n = 230); unfilled circle CS− 
pathogen present (n = 417); 
filled square CS− pathogen 
absent (n = 460). aFailure and 
relapse; CS corticosteroid; EOT 


























* P<0.001 vs CS+ pathogen absent, CS– pathogen absent / present
*
$
$ P<0.001 vs CS– pathogen absent
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both antibiotics in vitro. The better bacteriological efficacy 
of MXF in vivo could be due to its high intracellular activ-
ity, while AMC penetrates cells poorly [19, 20]. Intracel-
lular localization of non-typeable H. influenzae has been 
described in COPD and chronic upper respiratory infec-
tions, and likely promotes persistence and recurrence of 
this pathogen [21].
Sputum cultures are not widely used in the management 
of AECOPD due to their low sensitivity and specificity 
and a long turnaround time (up to 48 h); therefore, puru-
lent sputum has been advocated as a predictor of bacterial 
exacerbations and as a guide to the need for antibiotics [7, 
8, 22, 23]. In the MAESTRAL study, in which all rand-
omized patients had purulent sputum, MXF was superior to 
AMC when PPBs were present in the sputum [9]; however, 
both antibiotics were equally clinically effective in patients 
without PPBs. In our analysis, the additional prognostic 
factors besides sputum purulence that might have predicted 
a PPB in sputum were older age, history of cardiopulmo-
nary disease, FEV1 percent predicted (>30 vs <30 %), spu-
tum viscosity, green/brown sputum, wheeze at exacerbation 
and short-acting anti-cholinergic use. Although these were 
all statistically significant predictive factors (P < 0.1 in 
univariate analysis), the presence of any of these risk fac-
tors increased the pathogen isolation rate by a maximum 
of 10.9 %, and the highest bacterial isolation rate was still 
58.6 %. Furthermore, the ROC analysis (AUC = 0.593) 
suggests that the combination of these risk factors remains 
inadequate in predicting the presence of pathogenic bac-
teria in the sputum. Further research on sputum or blood 
biomarkers clearly associated with bacterial exacerbations 
and/or more reliable tests of the presence of bacteria in the 
airways other than sputum culture are greatly needed to 
support diagnosis.
The MAESTRAL study is the first study to show that 
bacterial eradication at EOT translates into longer-term 
clinical success [9]. In this analysis, we aimed to identify 
independent predictors of bacteriological eradication and 
success. We have found that among pathogen-positive 
patients who were treated with moxifloxacin, who received 
a prior course of antibiotic in the last 3 months, who had 
respiratory failure in the past, who had higher sputum vol-
ume at baseline, who were not infected by P. aeruginosa 
or any other resistant pathogen at enrolment, who had BMI 
≥20 kg/m2, and a body temperature ≥36 °C were more 
likely to achieve bacteriological eradication or success 
after antibiotic therapy. The surprising association between 
a prior course of antibiotic within the previous 3 months 
and confirmed eradication of bacteria may be the result of 
reduced overall bacterial load in the airways of patients that 
might translate into better clinical outcome from the sub-
sequent exacerbation. The results of a previous placebo-
controlled study in which AECOPD patients received six 
courses of moxifloxacin therapy in every 8 weeks had sig-
nificantly lower odds of a subsequent exacerbation [24]. 
The positive association between history of respiratory 
failure and the probability of bacteriological eradication 
seems counterintuitive; however, these patients might have 
received more supportive and respiratory therapies.
The co-administration of systemic corticosteroids for 
the current exacerbation was associated with lack of con-
firmed bacteriological eradication from sputum at EOT and 
lack of bacteriological success at 8 weeks post-therapy. 
Similarly, patients with maintenance LABA therapy had 
a significantly lower likelihood to achieve bacteriological 
success at both EOT and 8 weeks post-therapy. It is pos-
sible that administration of oral corticosteroids for the cur-
rent exacerbation and LABA therapy are markers of a more 
severe disease status in this analysis; and the more severe 
disease is linked with lower capability of antibiotics and 
the body’s immune system to eradicate bacterial pathogens 
[5]. Nevertheless, these observations in this patient popu-
lation warrant further investigation given the widespread 
use of LABA in stable COPD and oral corticosteroids for 
exacerbations.
Our analysis of the interaction of presence of bacte-
rial pathogens in sputum and systemic corticosteroid use 
revealed very interesting results. In patients not given oral 
corticosteroids, failure rates were linear and followed simi-
lar trends in pathogen positive and negative exacerbations. 
In corticosteroid-treated pathogen-positive patients, higher 
failure rates were observed at all time points. Conversely, 
in corticosteroid-treated patients with pathogen-negative 
exacerbations, failure rates remained low until EOT, then 
increased substantially to become similar to the corticos-
teroid-treated pathogen-positive patients and higher than 
patients not treated with corticosteroids. Though effective 
in relieving symptoms in exacerbations, corticosteroids 
have immunosuppressive effects that can interfere with 
clearance of infectious pathogens. Both innate and adap-
tive immune responses in the lung are required for patho-
gen clearance. Alveolar macrophages are key orchestrators 
for both innate and adaptive immune responses. Alveolar 
macrophages obtained from COPD patients have impaired 
phagocytic ability for, and suppressed cytokine response 
to, bacterial pathogens implicated in recurrent infections 
in COPD [25, 26]. In an in vivo mouse model of pneumo-
coccal lung infection and in vitro in alveolar macrophages, 
Stolberg et al. demonstrated that corticosteroids increased 
the early bacterial burden and impaired the phagocytic kill-
ing of pneumococci by alveolar macrophages [27]. A 7-day 
prior glucocorticoid exposure substantially weakened the 
adaptive immune signature of human monocyte-derived 
macrophages following stimulation with lipopolysaccha-
ride (LPS, endotoxin) in vitro [28]. Additional impairment 
by corticosteroids of the innate and adaptive responses of 
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lung macrophages to pathogens, which are already com-
promised in COPD, is likely to be a major contributor to 
diminished pathogen clearance and could explain our find-
ings. Interestingly, in a recent study by Bafadhel et al. 
patients without peripheral blood eosinophilia at exacerba-
tion who had more neutrophils and higher concentration of 
sputum bacteria, had a higher failure rate when given sys-
temic corticosteroids as compared with placebo [29]. These 
observations suggest that universal prescription of systemic 
corticosteroids for all severe AECOPD may not be optimal, 
especially when bacterial infection is a likely cause of the 
exacerbation.
Increased airway inflammation is present during an 
acute exacerbation and resolves with successful treatment 
[3, 30–33]. Evidence suggests that the link between bacte-
rial eradication and clinical resolution is the reduction in 
the level of inflammation after bacterial eradication [32, 
34, 35]. Persistence, superinfection or reinfection may also 
predispose patients for relapses leading to the vicious cycle 
between inflammation and infection [5]. For this reason, 
a high rate of bacterial eradication from the airways (spu-
tum) of AECOPD patients should be a key goal of antibi-
otic therapy, and a focus on bacterial eradication rather than 
simply on clinical resolution needs to be considered. Our 
data showed significant association between higher base-
line sputum volume and confirmed bacteriological eradica-
tion from the sputum at the end of antibiotic therapy. This 
significant association, however, was not present when pre-
sumed eradication was also analyzed in patients who were 
clinically cured at EOT and, therefore, could not provide 
sputum sample. Therefore, its significance in clinical prac-
tice remains elusive.
In summary, this paper presents a detailed analysis of 
microbiological outcomes in AECOPD, and reveals that 
H. influenzae may not be adequately eradicated by AMC. 
The study also showed that in patients with purulent spu-
tum clinical factors weakly predicted the presence of 
pathogens in sputum. Additionally, bacterial eradication 
was found to be impaired by systemic steroid use, anti-
biotic resistance and presence of P. aeruginosa. These 
observations suggest that sputum analysis (or a more pre-
cise rapid bacterial diagnostic test in the future) may be 
indicated to help optimize antibiotic therapy in patients 
with Anthonisen type I exacerbations who do not require 
hospitalization, particularly if they are at risk of being 
infected with P. aeruginosa or they receive concomitant 
systemic corticosteroids.
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